Strides Pharma Science (NSE:STAR) LT-Debt-to-Total-Asset: 0.09 (As of Mar. 2026)

What is Strides Pharma Science LT-Debt-to-Total-Asset?

Strides Pharma Science NSE:STAR -0.95% 68 LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹775.20 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Strides Pharma Science's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.09.

Strides Pharma Science's long-term debt to total assets ratio declined from Mar. 2025 (0.10) to Mar. 2026 (0.09). It may suggest that Strides Pharma Science is progressively becoming less dependent on debt to grow their business.

Strides Pharma Science (NSE:STAR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Strides Pharma Science LT-Debt-to-Total-Asset Related Terms

Strides Pharma Science LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science LT-Debt-to-Total-Asset Chart

Strides Pharma Science Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.20

0.13

0.10

0.09

Strides Pharma Science Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.00	0.09	0.00	0.09

68GF Score

Strides Pharma Science Ltd NSE:STAR

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Strides Pharma Science LT-Debt-to-Total-Asset Calculation

Strides Pharma Science's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	6041.56	/	69272.32
	=	0.09

Strides Pharma Science's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	6041.56	/	69272.32
	=	0.09

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.09 mean?

Strides Pharma Science (NSE:STAR) has a LT-Debt-to-Total-Asset of 0.09 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Strides Pharma Science and its competitors.

Is Strides Pharma Science's LT-Debt-to-Total-Asset too high?

Strides Pharma Science's current LT-Debt-to-Total-Asset is 0.09. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Strides Pharma Science's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Strides Pharma Science's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Strides Pharma Science stock overvalued right now?

Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹775.20, compared to a current price of ₹1,092.90 — trading 41% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,092.90 is trading 41% above its estimated GF Value™ of ₹775.20. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

LT-Debt-to-Total-Asset: 0.09
GF Value™: ₹775.20 vs. price of ₹1,092.90 (41% above fair value)
GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:500126 BOM:544222 BOM:544619 BOM:530549 BOM:512529 BOM:532872 BOM:530239 BOM:531599 BOM:543322 BOM:543748 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 532531:India

Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076

Website https://www.strides.com

Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.

68GF Score

Get the complete analysis for NSE:STAR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,092.90

Price

₹775.20

GF Value

View NSE:STAR Analysis

See LT-Debt-to-Total-Asset data for all stocks →